Production of human platelet lysate by use of ultrasound for ex vivo expansion of human bone marrow-derived mesenchymal stromal cells

Cytotherapy

Volumn 15, Issue 8, 2013, Pages 920-929

  Bernardi, Martina ^a,b   Albiero, Elena ^a,b   Alghisi, Alberta ^a   Chieregato, Katia ^a   Lievore, Chiara ^a   Madeo, Domenico ^b   Rodeghiero, Francesco ^a,b   Astori, Giuseppe ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

^b Fondazione Progetto Ematologia   (Italy)

Author keywords

Mesenchymal stromal cell; PDGF AB; Platelet lysate; Sonication

Indexed keywords

PLATELET DERIVED GROWTH FACTOR AB; CELL EXTRACT; PLATELET DERIVED GROWTH FACTOR; PLATELET-DERIVED GROWTH FACTOR AB; CULTURE MEDIUM;

ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL ASSAY; CELL DIFFERENTIATION; CELL EXPANSION; CELL FUNCTION; CELL GROWTH; CELL LINEAGE; CELL POPULATION; CONTROLLED STUDY; EX VIVO STUDY; FREEZE THAWING; GROWTH RATE; HUMAN; HUMAN CELL; IMAGE ANALYSIS; KARYOTYPING; MOLECULAR DYNAMICS; MOLECULAR IMAGING; PLATELET LYSATE; PROCEDURES CONCERNING CELLS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; BONE MARROW CELL; CELL CULTURE; CELL PROLIFERATION; CHEMISTRY; CULTURE MEDIUM; CULTURE TECHNIQUE; CYTOLOGY; MESENCHYMAL STROMA CELL; PDGF-AB; SECRETION (PROCESS); THROMBOCYTE; ULTRASOUND;

MESENCHYMAL STROMAL CELL; PDGF-AB; PLATELET LYSATE; SONICATION;

BLOOD PLATELETS; BONE MARROW CELLS; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL EXTRACTS; CELL LINEAGE; CELL PROLIFERATION; CELLS, CULTURED; CULTURE MEDIA, SERUM-FREE; HUMANS; MESENCHYMAL STROMAL CELLS; PLATELET-DERIVED GROWTH FACTOR; SONICATION;

EID: 84893471284     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2013.01.219     Document Type: Article

References (52)

1. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
2. Bruder S.P., Kurth A.A., Shea M., Hayes W.C., Jaiswal N., Kadiyala S. Bone regeneration by implantation of purified, culture-expanded human mesenchymal stem cells. JOrthop Res 1998, 16:155-162.
3. De Kok I.J., Peter S.J., Archambault M., van den Bos C., Kadiyala S., Aukhil I., et al. Investigation of allogeneic mesenchymal stem cell-based alveolar bone formation: preliminary findings. Clin Oral Implants Res 2003, 14:481-489.
4. Wakitani S., Goto T., Pineda S.J., Young R.G., Mansour J.M., Caplan A.I., et al. Mesenchymal cell-based repair of large, full-thickness defects of articular cartilage. JBone Joint Surg Am 1994, 76:579-592.
5. Awad H.A., Boivin G.P., Dressler M.R., Smith F.N., Young R.G., Butler D.L. Repair of patellar tendon injuries using a cell-collagen composite. JOrthop Res 2003, 21:420-431.
6. Hare J.M., Traverse J.H., Henry T.D., Dib N., Strumpf R.K., Schulman S.P., et al. Arandomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. JAm Coll Cardiol 2009, 54:2277-2286.
7. Meyer G.P., Wollert K.C., Lotz J., Pirr J., Rager U., Lippolt P., et al. Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur Heart J 2009, 30:2978-2984.
8. Bernardo M.E., Pagliara D., Locatelli F. Mesenchymal stromal cell therapy: a revolution in regenerative medicine?. Bone Marrow Transplant 2012, 47:164-171.
9. Horwitz E.M., Prockop D.J., Fitzpatrick L.A., Koo W.W., Gordon P.L., Neel M., et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999, 5:309-313.
10. Horwitz E.M., Gordon P.L., Koo W.K., Marx J.C., Neel M.D., McNall R.Y., et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci U S A 2002, 99:8932-8937.
11. Ringden O., Keating A. Mesenchymal stromal cells as treatment for chronic GVHD. Bone Marrow Transplant 2011, 46:163-164.
12. Ringden O., Uzunel M., Rasmusson I., Remberger M., Sundberg B., Lonnies H., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006, 81:1390-1397.
13. Le Blanc K., Rasmusson I., Sundberg B., Gotherstrom C., Hassan M., Uzunel M., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
14. Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
15. Draft guideline on the use of bovine serum in the manufacture of human biological products 2012, European Medicines Agency, European Medicines Agency, London, EMA/CHMP/BWP/457920/2012.
16. Guideline on the Requirements and Controls Applied to Bovine Serum Used in the Production of Immunological Veterinary Medicinal Products. Note for guidance on the use of bovine serum in the manufacture of human biological medicinal products 2003, EMEA, European Medicines Agency, London, CPMP/BWP/1793/02.
17. Note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products 2011, European Medicines Agency, European Medicines Agency, London.
18. Dimasi L. Meeting increased demands on cell-based processes by using defined media supplements. Bioprocess J 2011, 9:9.
19. Even M.S., Sandusky C.B., Barnard N.D. Serum-free hybridoma culture: ethical, scientific and safety considerations. Trends Biotechnol 2006, 24:105-108.
20. Doucet C., Ernou I., Zhang Y., Llense J.R., Begot L., Holy X., et al. Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. JCell Physiol 2005, 205:228-236.
21. Muller I., Kordowich S., Holzwarth C., Spano C., Isensee G., Staiber A., et al. Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM. Cytotherapy 2006, 8:437-444.
22. Bieback K., Hecker A., Kocaomer A., Lannert H., Schallmoser K., Strunk D., et al. Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells 2009, 27:2331-2341.
23. Fekete N., Rojewski M.T., Furst D., Kreja L., Ignatius A., Dausend J., et al. GMP-compliant isolation and large-scale expansion of bone marrow-derived MSC. PLoS One 2012, 7:e43255.
24. Avanzini M.A., Bernardo M.E., Cometa A.M., Perotti C., Zaffaroni N., Novara F., et al. Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood- and bone marrow-derived progenitors. Haematologica 2009, 94:1649-1660.
25. Reinisch A., Bartmann C., Rohde E., Schallmoser K., Bjelic-Radisic V., Lanzer G., et al. Humanized system to propagate cord blood-derived multipotent mesenchymal stromal cells for clinical application. Regen Med 2007, 2:371-382.
26. Naaijkens B.A., Niessen H.W., Prins H.J., Krijnen P.A., Kokhuis T.J., de Jong N., et al. Human platelet lysate as a fetal bovine serum substitute improves human adipose-derived stromal cell culture for future cardiac repair applications. Cell Tissue Res 2012, 348:119-130.
27. Cholewa D., Stiehl T., Schellenberg A., Bokermann G., Joussen S., Koch C., et al. Expansion of adipose mesenchymal stromal cells is affected by human platelet lysate and plating density. Cell Transplant 2011, 20:1409-1422.
28. Blande I.S., Bassaneze V., Lavini-Ramos C., Fae K.C., Kalil J., Miyakawa A.A., et al. Adipose tissue mesenchymal stem cell expansion in animal serum-free medium supplemented with autologous human platelet lysate. Transfusion 2009, 49:2680-2685.
29. Capelli C., Gotti E., Morigi M., Rota C., Weng L., Dazzi F., et al. Minimally manipulated whole human umbilical cord is a rich source of clinical-grade human mesenchymal stromal cells expanded in human platelet lysate. Cytotherapy 2011, 13:786-801.
30. Chieregato K., Albiero E., Castegnaro S., Bernardi M., d'Amore E.S., Zanon C., et al. Astudy on mutual interaction between cytokine induced killer cells and umbilical cord-derived mesenchymal cells: implication for their in-vivo use. Blood Cells Mol Dis 2012, 49:159-165.
31. Lucchini G., Introna M., Dander E., Rovelli A., Balduzzi A., Bonanomi S., et al. Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Biol Blood Marrow Transplant 2010, 16:1293-1301.
32. Perez-Simon J.A., Lopez-Villar O., Andreu E.J., Rifon J., Muntion S., Campelo M.D., et al. Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial. Haematologica 2011, 96:1072-1076.
33. Centeno C.J., Schultz J.R., Cheever M., Freeman M., Faulkner S., Robinson B., et al. Safety and complications reporting update on the re-implantation of culture-expanded mesenchymal stem cells using autologous platelet lysate technique. Curr Stem Cell Res Ther 2011, 6:368-378.
34. Castegnaro S., Chieregato K., Maddalena M., Albiero E., Visco C., Madeo D., et al. Effect of platelet lysate on the functional and molecular characteristics of mesenchymal stem cells isolated from adipose tissue. Curr Stem Cell Res Ther 2011, 6:105-114.
35. Bernardo M.E., Avanzini M.A., Perotti C., Cometa A.M., Moretta A., Lenta E., et al. Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell-therapy approaches: further insights in the search for a fetal calf serum substitute. JCell Physiol 2007, 211:121-130.
36. Abdelrazik H., Spaggiari G.M., Chiossone L., Moretta L. Mesenchymal stem cells expanded in human platelet lysate display a decreased inhibitory capacity on T- and NK-cell proliferation and function. Eur J Immunol 2011, 41:3281-3290.
37. Giacco F., Perruolo G., D'Agostino E., Fratellanza G., Perna E., Misso S., et al. Thrombin-activated platelets induce proliferation of human skin fibroblasts by stimulating autocrine production of insulin-like growth factor-1. FASEB J 2006, 20:2402-2404.
38. Kocaoemer A., Kern S., Kluter H., Bieback K. Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue. Stem Cells 2007, 25:1270-1278.
39. Kakudo N., Minakata T., Mitsui T., Kushida S., Notodihardjo F.Z., Kusumoto K. Proliferation-promoting effect of platelet-rich plasma on human adipose-derived stem cells and human dermal fibroblasts. Plast Reconstr Surg 2008, 122:1352-1360.
40. Schallmoser K., Bartmann C., Rohde E., Reinisch A., Kashofer K., Stadelmeyer E., et al. Human platelet lysate can replace fetalbovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion 2007, 47:1436-1446.
41. Fekete N., Gadelorge M., Furst D., Maurer C., Dausend J., Fleury-Cappellesso S., et al. Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components. Cytotherapy 2012, 14:540-554.
42. Salvade A., Della Mina P., Gaddi D., Gatto F., Villa A., Bigoni M., et al. Characterization of platelet lysate cultured mesenchymal stromal cells and their potential use in tissue-engineered osteogenic devices for the treatment of bone defects. Tissue Eng Part C Methods 2010, 16:201-214.
43. SE R. Human platelets contain phospholipase C that hydrolyzes polyphosphoinositides (phosphomonoesterase/calcium). Proc Nati Acad Sci USA 1983, 80:3.
44. Slezak S., Symer D.E., Shin H.S. Platelet-mediated cytotoxicity: role of antibody and C3, and localization of the cytotoxic system in membranes. JExp Med 1987, 166:489-505.
45. Vanschoonbeek K., Feijge M.A., Van Kampen R.J., Kenis H., Hemker H.C., Giesen P.L., et al. Initiating and potentiating roleof platelets in tissue factor-induced thrombin generation in the presence of plasma: subject-dependent variation in thrombogram characteristics. JThromb Haemost 2004, 2:476-484.
46. Riesz P., Kondo T. Free radical formation induced by ultrasound and its biological implications. Free Radic Biol Med 1992, 13:247-270.
47. Miller D.L., Pislaru S.V., Greenleaf J.E. Sonoporation: mechanical DNA delivery by ultrasonic cavitation. Somat Cell Mol Genet 2002, 27:115-134.
48. Flint E.B., Suslick K.S. The temperature of cavitation. Science 1991, 253:1397-1399.
49. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells: the International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
50. Harrison P., Cramer E.M. Plateletalpha-granules. Blood Rev 1993, 7:52-62.
51. Schallmoser K., Rohde E., Bartmann C., Obenauf A.C., Reinisch A., Strunk D. Platelet-derived growth factors for GMP-compliant propagation of mesenchymal stromal cells. Biomed Mater Eng 2009, 19:271-276.
52. Schallmoser K., Strunk D. Preparation of pooled human platelet lysate (pHPL) as an efficient supplement for animal serum-free human stem cell cultures. JVis Exp 2009, e1523. http://dx.doi.org/10.3791/1523.